Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 16Cyclophosphamide 8Nivolumab 7Gemcitabine 6Paclitaxel 5Drug Therapy 5Docetaxel 5fludarabine 4aldesleukin 4Oxaliplatin 4Fluorouracil 4Carboplatin 4ulixertinib 3spartalizumab 3Trastuzumab 3Radiotherapy 3Leucovorin 3Capecitabine 3trametinib 2tovorafenib 2pertuzumab 2pegilodecakin 2pazopanib 2palbociclib 2osimertinib 2enzalutamide 2cemiplimab 2atezolizumab 2Taxes 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × marizomib × Dermatologic × Clear all
NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡